ProfileGDS5678 / 1421545_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 74% 75% 71% 74% 76% 76% 74% 75% 74% 76% 74% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.909175
GSM967853U87-EV human glioblastoma xenograft - Control 24.9118574
GSM967854U87-EV human glioblastoma xenograft - Control 34.9076175
GSM967855U87-EV human glioblastoma xenograft - Control 44.6186171
GSM967856U87-EV human glioblastoma xenograft - Control 54.8943774
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9512976
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0123276
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8667474
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.936675
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8555674
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.084976
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8125274
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9102475
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.901775